ALERTS: PROCEDURES - FRANCE - PHARMACEUTICAL SECTOR – PAY FOR DELAY - SANCTIONS

Sanction: The Paris Court of Appeal reduces the penalty imposed on a pharmaceutical company by €4 million, but essentially confirms the French Competition Authority’s analysis on the delay in generic entry (Janssen-Cilag, Johnson & Johnson)

*This article is an automatic translation of the original article, provided here for your convenience. Read the original article. On 11 July 2019, the Paris Court of Appeal handed down a ruling in the case of the delay in the entry of generics of Durogesic. It will be recalled that by a decision rendered on December 20, 2017In its decision of 25 March 2008, the Competition Authority sanctioned the laboratory Janssen-Cilag, as the perpetrator, and its parent company Johnson & Johnson - imputability obliges - to the tune of EUR 25 million, for having carried out, from 25 March 2008 to mid-August 2009, that is to say, for 16 months, two practices constituting a complex and continuous infringement aimed at preventing, then to limit the penetration of generic competitors of the

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.

 

PDF Version

Author

  • L’actu-concurrence (Paris)

Quotation

Alain Ronzano, Sanction: The Paris Court of Appeal reduces the penalty imposed on a pharmaceutical company by €4 million, but essentially confirms the French Competition Authority’s analysis on the delay in generic entry (Janssen-Cilag, Johnson & Johnson), 11 July 2019, Concurrences N° 4-2019, Art. N° 91130, www.concurrences.com

Visites 565

All reviews